Phospholipase is one of a very complex group of enzymes that converts phospholipids into fatty acids and other compounds. The enzymatic reaction that phospholipases catalyze serves to define them. Phospholipase A, which has members A1 and A2, Phospholipase B, which can perform both A1 and A2 reactions, Phospholipase C, and Phospholipase D are the classes.
Fatty acids and lysophospholipids are produced when phospholipase A2 (PLA2) catalyzes the hydrolysis of the sn-2 position of glycerophospholipids. Phospholipase C (PLC) transforms inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) from phosphatidylinositol 4,5-bisphosphate (PIP2). DAG and IP3 each regulate a variety of cellular processes and serve as a starting point for the creation of additional significant signaling molecules. PLC serves as the hub of numerous significant interconnected regulatory networks. The production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes like membrane trafficking, actin cytoskeleton remodeling, cell proliferation, and cell survival, is carried out by the crucial enzyme phospholipase D (PLD).
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V33512 | LCL521 | 1226851-11-1 | LCL521 is an acid ceramidase (ACDase) inhibitor. |
|
V33513 | LCL521 dihydrochloride | 1226759-47-2 | LCL521 dihydrochloride (1,3DMG-B13 dihydrochloride)is a novel and potent acid ceramidase (ACDase) inhibitor. |
|
V73528 | LEI-401 | 2393840-15-6 | LEI-401 is a first-in-class, selective, BBB (blood-brain barrier)-passing NAPE-PLD (N-acylphosphoethanolamine phospholipase D) inhibitor (antagonist) with IC50 of 27 nM. |
|
V73526 | LFHP-1c | 2102347-47-5 | LFHP-1c is a PGAM5 inhibitor (antagonist) with neuro-protection activity in ischemic stroke. |
|
V73539 | Lp-PLA2-IN-10 | 2756855-45-3 | Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). |
|
V73542 | Lp-PLA2-IN-12 | 2637485-14-2 | Lp-PLA2-IN-12 (compound 19) is an Lp-PLA2 inhibitor. |
|
V73534 | Lp-PLA2-IN-13 | 2756855-62-4 | Lp-PLA2-IN-13 (compound 15) is a potent Lp-PLA2 inhibitor. |
|
V73551 | Lp-PLA2-IN-14 | 2756855-66-8 | Lp-PLA2-IN-14 (Compound 19) is an Lp-PLA2 inhibitor (antagonist) with pIC50 of 8.4 for rhLp-PLA2. |
|
V73537 | Lp-PLA2-IN-15 | 1865796-11-7 | Lp-PLA2-IN-15 (example 2) is a lipoprotein-associated phospholipase A2 (Lp-PLA 2) inhibitor that may be utilized in AD/Alzheimer's disease and other research. |
|
V73536 | Lp-PLA2-IN-16 | 1865780-73-9 | Lp-PLA2-IN-16 (example 1) is a lipoprotein-associated phospholipase A2 (Lp-PLA 2) inhibitor that may be utilized in AD/Alzheimer's disease and other research. |
|
V76776 | Melittin TFA (melittin trifluoroacetate; melittin trifluoroacetate) | Melittin TFA is a PLA2 activator that stimulates the activity of low molecular weight PLA2 without increasing the activity of high molecular weight PLA2. | |
|
V73532 | MJ33 lithium salt | 1007476-63-2 | MJ33 is an active site-directed, specific, competitive, reversible inhibitor of phospholipase A2 (PLA2). |
|
V73545 | MJ33-OH | 199106-13-3 | MJ33-OH is a metabolite of MJ33. |
|
V4495 | ML349 | 890819-86-0 | ML349 (ML-349) is a novel, potent,reversible, highly selective and specificacyl protein thioesterase 2(APT-2) inhibitor with aKiof 120 nM. |
|
V73546 | N-Stearoylsphingomyelin (N-Stearoyl-D-sphingomyelin) | 58909-84-5 | N-Stearoylsphingomyelin (N-Stearoyl-D-sphingomyelin) is a sphingomyelin that can inhibit phospholipase Cδ1 (PLCδ1). |
|
V80610 | nSMase2-IN-1 | nSMase2-IN-1 is an orally bioavailable neutral sphingomyelinase 2 (nSMase2) inhibitor (antagonist) with IC50 of 0.13 ± 0.06 μM. | |
|
V73541 | Phospholipase A2 (PLA2) | 9001-84-7 | Phospholipase A2 (PLA2) catalyzes the hydrolysis of the sn-2 position of membrane glycerophospholipids, releasing arachidonic acid (AA). |
|
V73531 | Phospholipase D (PLD) | 9001-87-0 | Phospholipase D (PLD), ie phospholipase D, is an enzyme of the phospholipase superfamily. |
|
V73549 | Pyrrophenone | 341973-06-6 | Pyrrophenone is a potent and specific inhibitor of cytosolic phospholipase A2α (cPLA2α) with IC50 of 4.2 nM. |
|
V73530 | ROC-0929 | 1048660-43-0 | ROC-0929 (compound 13a) is a potent and specific inhibitor of secreted phospholipase A2s (sPLA2s). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
